Table 1.
Open in new tab

Clinical and Demographic Characteristics of the Study Population

CovariateResult
Age, mean ± SD49.9 ± 16.0
Sex

  • Male

43 (61.4)

  • Female

27 (38.6)
Race

  • White

43 (61.4)

  • Unknown/not reported

18 (25.7)

  • Asian

6 (8.6)

  • Black

2 (2.9)

  • More than 1 race

1 (1.4)
Ethnicity

  • Not Hispanic or Latino

26 (37.1)

  • Hispanic or Latino

13 (18.6)

  • Unknown/not reported

31 (44.3)
Body mass index, median (IQR)27.6 (24.5–31.1)
Indication for HCT

  • Acute myelogenous leukemia

30 (42.9)

  • Acute lymphoblastic leukemia

9 (12.9)

  • Myelodysplastic syndrome

8 (11.4)

  • Chronic myelogenous leukemia

7 (10.0)

  • Chronic lymphocytic leukemia

2 (2.9)

  • Non-Hodgkin lymphoma

2 (2.9)

  • Aplastic anemia

1 (1.4)

  • Chronic myelomonocytic leukemia

1 (1.4)

  • Hodgkin lymphoma

1 (1.4)

  • Other

9 (12.9)
HCT source

  • Bone marrow

8 (11.4)

  • Cord blood

1 (1.4)

  • Peripheral blood

57 (81.4)

  • Missing

4 (5.7)
HCT donor type

  • HLA-matched related donor

24 (34.3)

  • HLA-matched unrelated donor

44 (62.9)

  • HLA-mismatched donor

1 (1.4)

  • Missing

1 (1.4)
Disease status at time of HCT

  • Active disease

13 (18.6)

  • Chronic phase (CML)

2 (2.9)

  • First complete remission

37 (52.9)

  • Second or more complete remission

11 (15.7)

  • Partial remissions

7 (10.0)
Intensity of conditioning regimen

  • Myeloablative

18 (25.7)

  • Myeloablative/ATG

22 (31.4)

  • Reduced intensity

6 (8.6)

  • Reduced intensity/ATG

24 (34.3)
Cytomegalovirus D/R status

  • D−/R–

15 (21.4)

  • D–/R+

23 (32.9)

  • D+/R–

5 (7.1)

  • D+/R+

27 (38.6)
CovariateResult
Age, mean ± SD49.9 ± 16.0
Sex

  • Male

43 (61.4)

  • Female

27 (38.6)
Race

  • White

43 (61.4)

  • Unknown/not reported

18 (25.7)

  • Asian

6 (8.6)

  • Black

2 (2.9)

  • More than 1 race

1 (1.4)
Ethnicity

  • Not Hispanic or Latino

26 (37.1)

  • Hispanic or Latino

13 (18.6)

  • Unknown/not reported

31 (44.3)
Body mass index, median (IQR)27.6 (24.5–31.1)
Indication for HCT

  • Acute myelogenous leukemia

30 (42.9)

  • Acute lymphoblastic leukemia

9 (12.9)

  • Myelodysplastic syndrome

8 (11.4)

  • Chronic myelogenous leukemia

7 (10.0)

  • Chronic lymphocytic leukemia

2 (2.9)

  • Non-Hodgkin lymphoma

2 (2.9)

  • Aplastic anemia

1 (1.4)

  • Chronic myelomonocytic leukemia

1 (1.4)

  • Hodgkin lymphoma

1 (1.4)

  • Other

9 (12.9)
HCT source

  • Bone marrow

8 (11.4)

  • Cord blood

1 (1.4)

  • Peripheral blood

57 (81.4)

  • Missing

4 (5.7)
HCT donor type

  • HLA-matched related donor

24 (34.3)

  • HLA-matched unrelated donor

44 (62.9)

  • HLA-mismatched donor

1 (1.4)

  • Missing

1 (1.4)
Disease status at time of HCT

  • Active disease

13 (18.6)

  • Chronic phase (CML)

2 (2.9)

  • First complete remission

37 (52.9)

  • Second or more complete remission

11 (15.7)

  • Partial remissions

7 (10.0)
Intensity of conditioning regimen

  • Myeloablative

18 (25.7)

  • Myeloablative/ATG

22 (31.4)

  • Reduced intensity

6 (8.6)

  • Reduced intensity/ATG

24 (34.3)
Cytomegalovirus D/R status

  • D−/R–

15 (21.4)

  • D–/R+

23 (32.9)

  • D+/R–

5 (7.1)

  • D+/R+

27 (38.6)

All data presented as n (%), mean ± standard deviation, or median (interquartile range, IQR) unless otherwise indicated.

Abbreviations: ATG, antithymocyte globulin; CML, chronic myelogenous leukemia; D, donor; HLA, human leukocyte antigen; R, recipient.

Table 1.
Open in new tab

Clinical and Demographic Characteristics of the Study Population

CovariateResult
Age, mean ± SD49.9 ± 16.0
Sex

  • Male

43 (61.4)

  • Female

27 (38.6)
Race

  • White

43 (61.4)

  • Unknown/not reported

18 (25.7)

  • Asian

6 (8.6)

  • Black

2 (2.9)

  • More than 1 race

1 (1.4)
Ethnicity

  • Not Hispanic or Latino

26 (37.1)

  • Hispanic or Latino

13 (18.6)

  • Unknown/not reported

31 (44.3)
Body mass index, median (IQR)27.6 (24.5–31.1)
Indication for HCT

  • Acute myelogenous leukemia

30 (42.9)

  • Acute lymphoblastic leukemia

9 (12.9)

  • Myelodysplastic syndrome

8 (11.4)

  • Chronic myelogenous leukemia

7 (10.0)

  • Chronic lymphocytic leukemia

2 (2.9)

  • Non-Hodgkin lymphoma

2 (2.9)

  • Aplastic anemia

1 (1.4)

  • Chronic myelomonocytic leukemia

1 (1.4)

  • Hodgkin lymphoma

1 (1.4)

  • Other

9 (12.9)
HCT source

  • Bone marrow

8 (11.4)

  • Cord blood

1 (1.4)

  • Peripheral blood

57 (81.4)

  • Missing

4 (5.7)
HCT donor type

  • HLA-matched related donor

24 (34.3)

  • HLA-matched unrelated donor

44 (62.9)

  • HLA-mismatched donor

1 (1.4)

  • Missing

1 (1.4)
Disease status at time of HCT

  • Active disease

13 (18.6)

  • Chronic phase (CML)

2 (2.9)

  • First complete remission

37 (52.9)

  • Second or more complete remission

11 (15.7)

  • Partial remissions

7 (10.0)
Intensity of conditioning regimen

  • Myeloablative

18 (25.7)

  • Myeloablative/ATG

22 (31.4)

  • Reduced intensity

6 (8.6)

  • Reduced intensity/ATG

24 (34.3)
Cytomegalovirus D/R status

  • D−/R–

15 (21.4)

  • D–/R+

23 (32.9)

  • D+/R–

5 (7.1)

  • D+/R+

27 (38.6)
CovariateResult
Age, mean ± SD49.9 ± 16.0
Sex

  • Male

43 (61.4)

  • Female

27 (38.6)
Race

  • White

43 (61.4)

  • Unknown/not reported

18 (25.7)

  • Asian

6 (8.6)

  • Black

2 (2.9)

  • More than 1 race

1 (1.4)
Ethnicity

  • Not Hispanic or Latino

26 (37.1)

  • Hispanic or Latino

13 (18.6)

  • Unknown/not reported

31 (44.3)
Body mass index, median (IQR)27.6 (24.5–31.1)
Indication for HCT

  • Acute myelogenous leukemia

30 (42.9)

  • Acute lymphoblastic leukemia

9 (12.9)

  • Myelodysplastic syndrome

8 (11.4)

  • Chronic myelogenous leukemia

7 (10.0)

  • Chronic lymphocytic leukemia

2 (2.9)

  • Non-Hodgkin lymphoma

2 (2.9)

  • Aplastic anemia

1 (1.4)

  • Chronic myelomonocytic leukemia

1 (1.4)

  • Hodgkin lymphoma

1 (1.4)

  • Other

9 (12.9)
HCT source

  • Bone marrow

8 (11.4)

  • Cord blood

1 (1.4)

  • Peripheral blood

57 (81.4)

  • Missing

4 (5.7)
HCT donor type

  • HLA-matched related donor

24 (34.3)

  • HLA-matched unrelated donor

44 (62.9)

  • HLA-mismatched donor

1 (1.4)

  • Missing

1 (1.4)
Disease status at time of HCT

  • Active disease

13 (18.6)

  • Chronic phase (CML)

2 (2.9)

  • First complete remission

37 (52.9)

  • Second or more complete remission

11 (15.7)

  • Partial remissions

7 (10.0)
Intensity of conditioning regimen

  • Myeloablative

18 (25.7)

  • Myeloablative/ATG

22 (31.4)

  • Reduced intensity

6 (8.6)

  • Reduced intensity/ATG

24 (34.3)
Cytomegalovirus D/R status

  • D−/R–

15 (21.4)

  • D–/R+

23 (32.9)

  • D+/R–

5 (7.1)

  • D+/R+

27 (38.6)

All data presented as n (%), mean ± standard deviation, or median (interquartile range, IQR) unless otherwise indicated.

Abbreviations: ATG, antithymocyte globulin; CML, chronic myelogenous leukemia; D, donor; HLA, human leukocyte antigen; R, recipient.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close